Back to Search
Start Over
Transfusion and Treatment of severe anaemia in African children (TRACT): a study protocol for a randomised controlled trial.
- Source :
-
Trials . 12/29/2015, Vol. 16 Issue 1, p1-14. 14p. 1 Diagram, 3 Charts. - Publication Year :
- 2015
-
Abstract
- <bold>Background: </bold>In sub-Saharan Africa, where infectious diseases and nutritional deficiencies are common, severe anaemia is a common cause of paediatric hospital admission, yet the evidence to support current treatment recommendations is limited. To avert overuse of blood products, the World Health Organisation advocates a conservative transfusion policy and recommends iron, folate and anti-helminthics at discharge. Outcomes are unsatisfactory with high rates of in-hospital mortality (9-10%), 6-month mortality and relapse (6%). A definitive trial to establish best transfusion and treatment strategies to prevent both early and delayed mortality and relapse is warranted.<bold>Methods/design: </bold>TRACT is a multicentre randomised controlled trial of 3954 children aged 2 months to 12 years admitted to hospital with severe anaemia (haemoglobin < 6 g/dl). Children will be enrolled over 2 years in 4 centres in Uganda and Malawi and followed for 6 months. The trial will simultaneously evaluate (in a factorial trial with a 3 x 2 x 2 design) 3 ways to reduce short-term and longer-term mortality and morbidity following admission to hospital with severe anaemia in African children. The trial will compare: (i) R1: liberal transfusion (30 ml/kg whole blood) versus conservative transfusion (20 ml/kg) versus no transfusion (control). The control is only for children with uncomplicated severe anaemia (haemoglobin 4-6 g/dl); (ii) R2: post-discharge multi-vitamin multi-mineral supplementation (including folate and iron) versus routine care (folate and iron) for 3 months; (iii) R3: post-discharge cotrimoxazole prophylaxis for 3 months versus no prophylaxis. All randomisations are open. Enrolment to the trial started September 2014 and is currently ongoing. Primary outcome is cumulative mortality to 4 weeks for the transfusion strategy comparisons, and to 6 months for the nutritional support/antibiotic prophylaxis comparisons. Secondary outcomes include mortality, morbidity (haematological correction, nutritional and infectious), safety and cost-effectiveness.<bold>Discussion: </bold>If confirmed by the trial, a cheap and widely available 'bundle' of effective interventions, directed at immediate and downstream consequences of severe anaemia, could lead to substantial reductions in mortality in a substantial number of African children hospitalised with severe anaemia every year, if widely implemented.<bold>Trial Registration: </bold>Current Controlled Trials ISRCTN84086586 , Approved 11 February 2013. [ABSTRACT FROM AUTHOR]
- Subjects :
- *ANEMIA in children
*CHILDREN
*RANDOMIZED controlled trials
*MALARIA
*ANTIBIOTIC prophylaxis
*SEPSIS
*MICRONUTRIENTS
*HEMOGLOBINS
*ANEMIA diagnosis
*ANEMIA treatment
*AGE distribution
*ANEMIA
*ANTHELMINTICS
*BLOOD transfusion
*CHILD mortality
*DIETARY supplements
*DRUG administration
*EXPERIMENTAL design
*HEALTH status indicators
*HOSPITAL admission & discharge
*INFANT mortality
*RESEARCH protocols
*PATIENTS
*RESEARCH funding
*TIME
*VITAMINS
*DISEASE relapse
*TREATMENT effectiveness
*SEVERITY of illness index
*HOSPITAL mortality
*NUTRITIONAL status
Subjects
Details
- Language :
- English
- ISSN :
- 17456215
- Volume :
- 16
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Trials
- Publication Type :
- Academic Journal
- Accession number :
- 112006614
- Full Text :
- https://doi.org/10.1186/s13063-015-1112-4